Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders Until January 12, 2024
Aridis Pharmaceuticals, Inc. (OTC QB: ARDS) today announced that its 2023 Annual Meeting of Stockholders ("Annual Meeting"), scheduled for Friday, December 15, 2023, was convened and adjourned, without any business being conducted, due to lack of the requisite quorum.
GlobeNewswireDec 15, 2023 16:15 ET
HC Wainwright & Co. Reiterates Buy on Aridis Pharmaceuticals, Maintains $2 Price Target
HC Wainwright & Co. analyst Vernon Bernardino reiterates Aridis Pharmaceuticals (OTC:ARDS) with a Buy and maintains $2 price target.
BenzingaNov 6, 2023 07:05 ET
Promising Developments and Value Proposition: A Buy Rating Analysis of Aridis Pharmaceuticals
TipRanksNov 6, 2023 06:33 ET
Aridis Pharmaceuticals Q3 EPS $0.00 Up From $(0.47) YoY, Sales $417.00K Up From $399.00K YoY
Aridis Pharmaceuticals Q3 EPS $0.00 Up From $(0.47) YoY, Sales $417.00K Up From $399.00K YoY
BenzingaNov 3, 2023 16:16 ET
Aridis Pharmaceuticals Price Target Cut to $2.00/Share From $10.00 by HC Wainwright & Co.
Aridis Pharmaceuticals Price Target Cut to $2.00/Share From $10.00 by HC Wainwright & Co.
Dow JonesOct 20, 2023 14:04 ET
Aridis Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Aridis Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow JonesOct 20, 2023 14:04 ET
HC Wainwright & Co. Maintains Buy on Aridis Pharmaceuticals, Lowers Price Target to $2
HC Wainwright & Co. analyst Vernon Bernardino maintains Aridis Pharmaceuticals with a Buy and lowers the price target from $10 to $2.
Analyst UpgradesOct 20, 2023 13:54 ET
Aridis Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 10/20/2023 3821.57% HC Wainwright & Co. $10 → $2 Maintains Buy 01/26/2023 19507.84% HC Wainwright & Co. $1
BenzingaOct 20, 2023 13:52 ET
FDA's Qualified Infectious Disease Product Designation Bolsters Aridis Pharmaceuticals' Investment Appeal: An Analyst's Buy Recommendation
TipRanksOct 20, 2023 10:35 ET
Reviva Pharmaceuticals Holdings, Inc. and Aridis Pharmaceuticals, Inc. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / September 22, 2023 / RedChip Companies will air interviews with Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and Aridis Pharmaceuticals, Inc. (OTC:ARDS) on The RedChi
AccesswireSep 22, 2023 13:30 ET
Aridis Pharmaceuticals, Inc., Genetic Technologies Limited, and American Resources Corporation Interviews to Air on the RedChip Money Report on Bloomberg TV
AccesswireSep 15, 2023 09:01 ET
Aridis Pharmaceuticals Announces $2 Million Offering to Fund Working Capital Needs
Seeking AlphaAug 2, 2023 10:21 ET
Aridis Pharmaceuticals Announces $2 Million Offering
Aridis Pharmaceuticals, Inc. (OTC: ARDS) today announced the pricing of an offering of 10,000,000 shares of the Company's common stock and accompanying warrants to purchase up to 10,000,000 shares of common stock at a combined offering price of $0.20 per share of common stock and accompanying warrant.
GlobeNewswireAug 2, 2023 08:17 ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersEtao International Co (NASDAQ:ETAO) shares rose 10.3% to $0.48 during Tuesday's after-market session. The market value of their outstanding shares is at $49.1 million. Virax Biolabs Group (NASD
BenzingaJul 18, 2023 17:32 ET
Sector Update: Health Care Stocks Steady Premarket Tuesday
Health care stocks were steady premarket Tuesday as the Health Care Select Sector SPDR Fund (XLV) was up a slight 0.1% and iShares Biotechnology ETF (IBB) was flat. Masimo (MASI) was slipping past 28%
MT NewswiresJul 18, 2023 09:17 ET
Why Are Aridis Pharmaceuticals Shares Moving Higher Today?
Aridis Pharmaceuticals Inc (NASDAQ:ARDS) shares are gaining after announcing positive European Medicines Agency feedback on its proposed single confirmatory Phase 3 study of investigational monoclonal
BenzingaJul 18, 2023 09:09 ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersBiophytis (NASDAQ:BPTS) shares increased by 45.2% to $3.21 during Tuesday's pre-market session. The market value of their outstanding shares is at $9.9 million. Aridis Pharmaceuticals (NASDAQ:A
BenzingaJul 18, 2023 09:06 ET
Update: Aridis Pharmaceuticals, European Regulator Agree on Pneumonia Phase 3 Study Parameters; Shares Jump Premarket
(Updates with the stock move in the headline and the last paragraph.) Aridis Pharmaceuticals (ARDS) said late Monday it reached an agreement with the European Medicines Agency on the overall design, e
MT NewswiresJul 18, 2023 06:10 ET
12 Health Care Stocks Moving In Monday's After-Market Session
GainersAridis Pharmaceuticals (NASDAQ:ARDS) shares increased by 89.5% to $0.5 during Monday's after-market session. At the close, Aridis Pharmaceuticals's trading volume reached 8.1 million shares. Th
BenzingaJul 17, 2023 17:32 ET
Aridis Pharmaceuticals Reaches Agreement for Phase 3 Study of Pneumonia Treatment in Europe; Shares Jump After Hours
Aridis Pharmaceuticals (ARDS) said late Monday it reached an agreement with the European Medicines Agency on the overall design, endpoints, and patient populations in its proposed single confirmatory
MT NewswiresJul 17, 2023 16:59 ET
No Data
No Data